BAP regimen

chemotherapy protocol consisting of above cpds; used in treatment of advanced thyroid cancer

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Chen, Jing: 1 article (05/2013)
2.	Gálvez-Peralta, Marina: 1 article (05/2013)
3.	Miller, Marian L: 1 article (05/2013)
4.	Nebert, Daniel W: 1 article (05/2013)
5.	Shi, Zhanquan: 1 article (05/2013)

1.	Neoplasms (Cancer) 05/01/2013 - "Striking increases or decreases were found in 26 cancer-related genes plus eight Serpin genes in DKO, but not in 1a1KO or WT, mice on this BaP regimen; of the 26, 8 were RAS-related oncogenes. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/01/2013 - "Cyp1a1/1b1(-/-) double-knockout (DKO) mice on this BaP regimen show no PSI adenocarcinoma, but instead preputial gland duct (PGD) squamous cell carcinoma (SCC) occurs by 12 weeks. "
3.	Adenocarcinoma 05/01/2013 - "In contrast, we found that global knockout of the Cyp1a1 gene (1a1KO) results in proximal small intestine (PSI) adenocarcinoma within 8-12 weeks on this BaP regimen; striking compensatory increases in PSI CYP1B1 likely participate in initiation of adenocarcinoma in 1a1KO mice. " 05/01/2013 - "Cyp1a1/1b1(-/-) double-knockout (DKO) mice on this BaP regimen show no PSI adenocarcinoma, but instead preputial gland duct (PGD) squamous cell carcinoma (SCC) occurs by 12 weeks. "